

~~D¹ Concl'd~~
elastase or plasmin activity or can be treated by the inhibition of normal leucocytic elastase or plasmin activity, said method comprising administering an effective amount of boswellic acid, a physiologically acceptable salt, a derivative, a salt of the derivative [or] a plant [preparation] extract containing boswellic acid, or combinations thereof to [prevent and/or] combat said diseases to a mammalian organism in need of such [prevention and/or] combating.

D²
16. (Twice Amended) The method as claimed in claim 10, wherein a [pharmaceutical compound] pharmaceutically acceptable carrier or diluent is also present.

~~Subt F2
D³~~
17. (Amended) A method for combating tumors and neoplasms or tumor metastases which are caused by increased plasmin activity or can be treated by the inhibition of normal leucocytic elastase or plasmin activity, said method comprising administering an effective amount of boswellic acid, a physiologically acceptable salt, a derivative, a salt of the derivative, [or] a plant [preparation] extract containing boswellic acid, or combinations thereof to combat said tumors and neoplasms or tumor metastases to a mammalian organism in need of such combating.

~~D⁴ Subt G2~~
22. (Amended) The method as claimed in claim 17, wherein a [pharmaceutical compound] pharmaceutically acceptable carrier or diluent is also present.

24. (Amended) The method as claimed in claim 10, wherein said plant [preparation] extract is obtained from resin.

D⁵
25. (Amended) The method as claimed in claim 10, wherein the effective amount of boswellic acid, a physiologically acceptable salt, a derivative, a salt of the derivative [or] a plant [preparation] extract containing boswellic acid, or combinations thereof is administered together with a [pharmaceutical compound] pharmaceutically acceptable carrier or diluent.

Please add the following new claims:

D⁶
--27. The method as claimed in claim 10, wherein said plant extract is a olibanum extract.--

REMARKS

Entry of the foregoing, reexamination and further and favorable reconsideration of the subject application in light of the following remarks, pursuant to and consistent with 37 C.F.R. § 1.112, are respectfully requested.

By the present amendment, claims 23 and 26 have been canceled, without prejudice or disclaimer to the subject matter disclosed therein. Claim 10 has been amended to remove recitation of "preventing and/or". Claims 10, 17, 24 and 25 have been amended to delete "plant preparation" and insert in place thereof "plant extract". Support for this amendment to the claims may be found, at the very least, on page 12, lines 9-13, of the